Executive Summary

Investment Thesis: Centene Corporation operates one of the largest government-sponsored healthcare plans in the U.S. and has meaningful scale in Medicaid and Medicare Advantage. Recent earnings showed strong revenue but material losses, and management withdrew 2025 guidance citing ACA market and Medicaid cost headwinds. The company is implementing leadership changes and community investments that may improve execution, while valuation metrics imply risk is priced in relative to peers. Your view of CNC should hinge on how you weigh near-term membership and cost trends against long-term scale and potential margin recovery.

Current Price: $35.73 | Key Metric: P/B 1.01 | Stance: NEUTRAL

Company Overview

Centene Corporation ($CNC) is a diversified, multi-national health care enterprise focused on government-sponsored and commercial managed care programs. The company provides health insurance to individuals through Medicaid, Medicare Advantage, ACA marketplaces, and commercial offerings, alongside ancillary services through subsidiaries such as Health Net.

Key Products & Competitive Position

Core Business: Managed care plans for Medicaid, Medicare Advantage, and ACA marketplaces across multiple U.S. states.
Key Products: Medicaid managed care, Medicare Advantage plans, ACA marketplace plans, specialty services and behavioral health programs.
Competitive Moat: Large scale in Medicaid and government-sponsored programs, extensive state-level plan footprint, and integrated care management capabilities that support cost containment and network relationships.

Recent Developments

In early April 2026 Centene announced a new executive leadership structure intended to sharpen operational accountability. The company also paused 2025 guidance after noting higher-than-expected risk in ACA marketplaces and rising Medicaid cost trends. Separately, Health Net, a Centene company, invested $6 million to expand behavioral health housing and care in Los Angeles, underscoring the company's community and social-determinants-of-health focus.

Financial Snapshot

Market Cap$17.27B

P/E RatioN/A (TTM EPS -$13.62)

52-Week Range$25.08 - $66.03

Dividend Yield0.0%

EPS (TTM)-$13.62

ROE-27.74%

Revenue & Earnings Trends

Revenue remains substantial, with Q4 FY2025 reported revenue near $49.7 billion. Despite top-line growth, Centene recorded a sizable net loss in Q4 2025, reported in coverage as around $1.10 billion. The loss reflects elevated medical costs in Medicaid and ACA lines plus reserve and risk adjustment volatility. Analysts are modeling a return to positive adjusted earnings in 2026, with some projecting adjusted EPS north of $3.00, though timing depends on Medicaid membership stabilization and ACA market outcomes.

Balance Sheet Highlights

Centene's balance sheet shows modest liquidity with a current ratio near 1.10. The company carries material operating liabilities inherent to prepaid health plans. Tangible book value is compressed, reflected in a P/B of 1.01. Leverage and capital allocation have been nuanced by recent losses and working capital swings, and investors should watch free cash flow and reserve levels closely.

Valuation Analysis

Current Valuation Metrics

Forward P/E13.8vs Industry: ~15-18

PEG Ratio~1.7Growth-adjusted

EV/EBITDA~3.9vs Historical: higher

P/S Ratio~0.10vs Peers: lower

Historical Comparison

On several multiples Centene trades at discounted levels relative to longer-term averages and peers. EV/EBITDA and P/S are low, reflecting the market pricing of near-term earnings risk. The stock's 52-week high of $66 implies substantial prior multiple expansion that has since reversed. Current valuation embeds a recovery expectation, but not full normalization to prior peak multiples.

Fair Value Estimate

Using a blend of multiples and conservative DCF inputs that assume adjusted EPS recovery to the mid-single digits per share by 2027 and normalized margins thereafter, a fair value range of $38 to $50 per share emerges. That range is sensitive to Medicaid cost trends and ACA enrollment assumptions. At the midpoint near $44, market-implied upside from today's price is roughly 20 to 25 percent, consistent with current analyst averages, but downside remains if outflows or cost pressures persist.

Competitive Landscape

Market Position

Market Share: Significant national footprint across Medicaid and Medicare lines | Ranking: Top 3 Medicaid managed care providers in the U.S.

Key Competitors

$UNHLarge national insurer with strong Medicare Advantage and diversified services.

$CVSIntegrated PBM and insurer with retail and care-delivery assets.

$HUMMajor Medicare Advantage player with scale and clinical programs.

Competitive Advantages

Moat 1: Scale in Medicaid administration and state plan relationships reduce per-member administrative costs.
Moat 2: Integrated local plan operations, including Health Net, provide regional expertise and cross-selling opportunities.
Moat 3: Investments in behavioral health and social determinants programs can improve outcomes and lower long-term medical spend.

Earnings Track Record

Last 4 Quarters: 2 beats / 2 misses

Recent Earnings History

Q4 2025Net loss ~$1.10B, Revenue $49.7BMISS

Q3 2025Adjusted results suggested in-line to modest beat on operating metricsBEAT

Q2 2025Operational pressure from Medicaid cost trendsMISS

Q1 2025Adjusted EPS showed resilienceBEAT

Guidance Trend

Importantly, Centene withdrew 2025 guidance after noting greater-than-anticipated risk in ACA marketplaces and rising Medicaid cost trends. Management communicated that 2026 adjusted EPS expectations could be positive, but timing and calibration depend on membership trends, reserve adequacy, and policy outcomes. The guidance withdrawal increases short-term uncertainty and gives analysts cause to re-model assumptions.

Analyst Sentiment

Consensus Rating: Hold

Strong Buy: 3 Buy: 5 Hold: 16 Sell: 2

Price Targets

Low: $32
Mean: $44.18 (+23.6% upside)
High: $70

Recent Analyst Actions

Cantor Fitzgerald reiterated a Neutral rating in February 2026 with a $41 price target. Several analysts are revisiting models following the guidance withdrawal and Q4 results. The dispersion in price targets reflects divergent views on Medicaid trends, potential ACA premium pressure, and the pace of margin recovery.

Recent News & Catalysts

Key Developments

Leadership Restructure (4/6/2026): Centene announced two new executive roles to sharpen accountability and execution at the corporate level.
Guidance Withdrawal (4/4/2026): The company withdrew 2025 guidance citing ACA marketplace risk and rising Medicaid costs, increasing modeling uncertainty.
Community Investment (4/2/2026): Health Net and the Centene Foundation committed $6M to expand behavioral health housing and services in Los Angeles.

Upcoming Catalysts

Next Earnings: 2026-04-28 Before Market | Key Events: Q1 2026 results, updated management commentary on Medicaid membership, reserve positions, ACA marketplace performance, and any incremental guidance or targets.

Technical Outlook

Current Price: $35.73 vs 52-Week High: $66.03 (-45.9% from high)

Trend Analysis

The stock has retraced a large portion of prior gains and is trading nearer the lower half of its 52-week range. Momentum indicators have cooled since the 2025 peak, reflecting fundamental concerns. For traders, the trend is range-bound to slightly bearish until management provides clearer visibility on Medicaid and ACA trajectories.

Key Levels

Resistance: $40, $50
Support: $30, $25

Bull vs Bear Case

Bull Case

Catalyst 1: Management stabilizes Medicaid cost trends and membership, allowing margins to re-expand.
Catalyst 2: ACA marketplace pricing and risk adjustment normalize, reducing reserve volatility and improving adjusted EPS.
Catalyst 3: Continued community investments and operational improvements translate into better utilization management and lower medical costs.

Bull Target: $55 (+54%)

Bear Case

Risk 1: Medicaid membership declines and higher-than-expected medical costs persist, pressuring margins and cash flow.
Risk 2: ACA marketplace volatility forces premium concessions or weak enrollment, amplifying losses.
Risk 3: Legal, regulatory, or reserve surprises could materially hurt earnings and capital position.

Bear Target: $25 (-30%)

Risks to Consider

Valuation Risk: Earnings are volatile and TTM EPS is deeply negative, which makes multiples sensitive to small changes in forecasts.
Competitive Risk: Medicaid and Medicare Advantage markets are competitive and state-level policy shifts can affect membership and pricing.
Macro Risk: Broader healthcare inflation and cost trends could continue to pressure margins across payor peers.
Execution Risk: Management must execute on cost controls, reserves and membership retention to achieve modeled recoveries; a failure to do so would increase downside risk.

Bottom Line

Investment Verdict: NEUTRAL

Centene is a strategically important player in government-sponsored healthcare with scale advantages that can drive attractive long-term returns if execution improves. Near term, ACA marketplace volatility, rising Medicaid cost trends, and guidance uncertainty increase downside risk. Analysts and market pricing reflect a balance of potential recovery and execution risk, leaving a neutral stance for the current environment.

Action Items for Investors

Long-term investors: Monitor Q1 2026 results and management commentary on Medicaid trends and reserve levels. Consider whether your long-term thesis is intact based on improving medical cost trends and management execution.
Short-term traders: Watch technical levels at $30 and $40 for potential entries and exits. Be prepared for heightened volatility around the April 28 earnings release.
Risk management: Rebalance position sizes to reflect heightened earnings uncertainty and consider using stop loss or hedging strategies if you hold material exposure.

What to Watch This Week

Any pre-earnings commentary from management about Q1 trends or updated guidance timing.
Analyst model revisions and price target updates following new guidance or executive changes.
State-level Medicaid developments or ACA enrollment updates that could materially affect near-term revenue and expense assumptions.

CNC: Guidance Uncertainty Meets Valuation Repricing